NCT04184232View on ClinicalTrials.gov

Treatment of Recurrent Bladder Cancer With Dendritic Cells

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Bladder Cancer
Interventions
BIOLOGICAL

Dendritic cells

Autologous dendritic cells primed with muc-1/wt-1 peptides

OTHER

Standard treatment according to the Clinical protocols

Standard treatment of bladder cancer according to the Clinical protocols

Trial Locations (1)

220072

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk

All Listed Sponsors
collaborator

Belarusian State Medical University

OTHER

lead

Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus

OTHER_GOV

NCT04184232 - Treatment of Recurrent Bladder Cancer With Dendritic Cells | Biotech Hunter | Biotech Hunter